SQZ Biotechnologies Competitors

SQZ Biotechnologies (NYSE:SQZ) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and AlloVir, as provided by MarketBeat.

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. AlloVir has a consensus target price of $48.75, suggesting a potential upside of 110.04%. Given SQZ Biotechnologies' higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than AlloVir.

Valuation and Earnings

This table compares SQZ Biotechnologies and AlloVir's revenue, earnings per share (EPS) and valuation.

Insider and Institutional Ownership

32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and AlloVir's net margins, return on equity and return on assets.

SQZ Biotechnologies (NYSE:SQZ) and Kymera Therapeutics (NASDAQ:KYMR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and Kymera Therapeutics, as provided by MarketBeat.

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. Kymera Therapeutics has a consensus target price of $48.6667, suggesting a potential upside of 45.53%. Given SQZ Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than Kymera Therapeutics.

Valuation and Earnings

This table compares SQZ Biotechnologies and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Insider and Institutional Ownership

37.8% of Kymera Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and Kymera Therapeutics' net margins, return on equity and return on assets.

Summary

SQZ Biotechnologies beats Kymera Therapeutics on 3 of the 4 factors compared between the two stocks.

SQZ Biotechnologies (NYSE:SQZ) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and REGENXBIO, as provided by MarketBeat.

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. REGENXBIO has a consensus target price of $62.50, suggesting a potential upside of 77.71%. Given SQZ Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than REGENXBIO.

Valuation and Earnings

This table compares SQZ Biotechnologies and REGENXBIO's revenue, earnings per share (EPS) and valuation.

SQZ Biotechnologies has higher earnings, but lower revenue than REGENXBIO.

Insider and Institutional Ownership

75.2% of REGENXBIO shares are owned by institutional investors. 14.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and REGENXBIO's net margins, return on equity and return on assets.

Summary

SQZ Biotechnologies beats REGENXBIO on 5 of the 9 factors compared between the two stocks.

SQZ Biotechnologies (NYSE:SQZ) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and C4 Therapeutics, as provided by MarketBeat.

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. C4 Therapeutics has a consensus target price of $44.50, suggesting a potential upside of 36.25%. Given SQZ Biotechnologies' higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than C4 Therapeutics.

Valuation and Earnings

This table compares SQZ Biotechnologies and C4 Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares SQZ Biotechnologies and C4 Therapeutics' net margins, return on equity and return on assets.

Summary

SQZ Biotechnologies beats C4 Therapeutics on 2 of the 2 factors compared between the two stocks.

SQZ Biotechnologies (NYSE:SQZ) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Profitability

This table compares SQZ Biotechnologies and Replimune Group's net margins, return on equity and return on assets.

Insider and Institutional Ownership

55.8% of Replimune Group shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and Replimune Group, as provided by MarketBeat.

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. Replimune Group has a consensus target price of $56.00, suggesting a potential upside of 86.23%. Given SQZ Biotechnologies' higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than Replimune Group.

Valuation and Earnings

This table compares SQZ Biotechnologies and Replimune Group's revenue, earnings per share (EPS) and valuation.

SQZ Biotechnologies (NYSE:SQZ) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares SQZ Biotechnologies and Alector's net margins, return on equity and return on assets.

Insider & Institutional Ownership

61.5% of Alector shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for SQZ Biotechnologies and Alector, as provided by MarketBeat.com.

SQZ Biotechnologies presently has a consensus price target of $38.3333, suggesting a potential upside of 180.62%. Alector has a consensus price target of $33.6667, suggesting a potential upside of 93.82%. Given SQZ Biotechnologies' higher probable upside, equities research analysts clearly believe SQZ Biotechnologies is more favorable than Alector.

Valuation & Earnings

This table compares SQZ Biotechnologies and Alector's top-line revenue, earnings per share (EPS) and valuation.

SQZ Biotechnologies has higher earnings, but lower revenue than Alector.

Summary

SQZ Biotechnologies beats Alector on 4 of the 7 factors compared between the two stocks.